BioDelivery Sciences International (FRA:BD5) Interest Expense : €-6.4 Mil (TTM As of Dec. 2021)

View and export this data going back to 2004. Start your Free Trial

What is BioDelivery Sciences International Interest Expense?

Interest Expense is the amount reported by a company or individual as an expense for borrowed money. BioDelivery Sciences International's interest expense for the three months ended in Dec. 2021 was € -1.4 Mil. Its interest expense for the trailing twelve months (TTM) ended in Dec. 2021 was €-6.4 Mil.

Interest Coverage is a ratio that determines how easily a company can pay interest expenses on outstanding debt. It is calculated by dividing a company's Operating Income(EBIT) by its Interest Expense. BioDelivery Sciences International's Operating Income for the three months ended in Dec. 2021 was € 8.0 Mil. BioDelivery Sciences International's Interest Expense for the three months ended in Dec. 2021 was € -1.4 Mil. BioDelivery Sciences International's Interest Coverage for the quarter that ended in Dec. 2021 was 5.90. The higher the ratio, the stronger the company's financial strength is. Note: If both Interest Expense and Interest Income are empty, while Net Interest Income is negative, then use Net Interest Income as Interest Expense.

BioDelivery Sciences International Interest Expense Historical Data

The historical data trend for BioDelivery Sciences International's Interest Expense can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

BioDelivery Sciences International Interest Expense Chart

BioDelivery Sciences International Annual Data

Trend

Dec12

Dec13

Dec14

Dec15

Dec16

Dec17

Dec18

Dec19

Dec20

Dec21

Interest Expense

Get a 7-Day Free Trial

-7.25

-8.96

-17.14

-5.77

-6.63

BioDelivery Sciences International Quarterly Data
	Mar17	Jun17	Sep17	Dec17	Mar18	Jun18	Sep18	Dec18	Mar19	Jun19	Sep19	Dec19	Mar20	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21
Interest Expense	Get a 7-Day Free Trial															-1.66	-1.66	-1.66	-1.69	-1.36

BioDelivery Sciences International Interest Expense Calculation

Interest Expense is the amount reported by a company or individual as an expense for borrowed money.

Interest Expense for the trailing twelve months (TTM) ended in Dec. 2021 adds up the quarterly data reported by the company within the most recent 12 months, which was €-6.4 Mil.

BioDelivery Sciences International (FRA:BD5) Interest Expense Explanation

Note: If both Interest Expense and Interest Income are empty, while Net Interest Income is negative, then use Net Interest Income as Interest Expense.

BioDelivery Sciences International's Interest Expense for the three months ended in Dec. 2021 was €-1.4 Mil. Its Operating Income for the three months ended in Dec. 2021 was €8.0 Mil. And its Long-Term Debt & Capital Lease Obligation for the three months ended in Dec. 2021 was €47.9 Mil.

BioDelivery Sciences International's Interest Coverage for the quarter that ended in Dec. 2021 is calculated as

Interest Coverage	=	-1	*	Operating Income (Q: Dec. 2021 )	/	Interest Expense (Q: Dec. 2021 )
	=	-1	*	8.011	/	-1.358
	=	5.90

The higher the ratio, the stronger the company's financial strength is.

BioDelivery Sciences International (FRA:BD5) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » BioDelivery Sciences International Inc (FRA:BD5) » Definitions » Interest Expense

Comparable Companies

Traded in Other Exchanges

N/A

Address

4131 ParkLake Avenue, Suite 225, Raleigh, NC, USA, 27612

Website

http://www.bdsi.com

BioDelivery Sciences International Inc is a rapidly growing commercial-stage specialty pharmaceutical company dedicated to patients living with chronic pain. The company is utilizing its novel and proprietary BioErodible MucoAdhesive (BEMA) technology and other drug delivery technologies to develop and commercialize, either on its own or in partnership with third parties, new applications of therapies aimed at addressing important unmet medical needs. Its products include Belbuca and Symproic.

BioDelivery Sciences International (FRA:BD5) Headlines

No Headlines